推荐产品
生物来源
mouse
质量水平
抗体形式
purified antibody
抗体产品类型
primary antibodies
克隆
MS110, monoclonal
表单
liquid
包含
≤0.1% sodium azide as preservative
种属反应性
human
制造商/商品名称
Calbiochem®
储存条件
do not freeze
同位素/亚型
IgG1
运输
wet ice
储存温度
2-8°C
靶向翻译后修饰
unmodified
基因信息
human ... BRCA1(672)
一般描述
可识别MCF-7细胞中的~220 kDa BRCA1蛋白。不与血型抗原或生长因子受体（如EGFR）发生交叉反应。根据美国专利号5,753,441和6,162,897的许可证销售。
抗BRCA1（Ab-1），小鼠单克隆，克隆MS110，可识别MCF-7细胞中的~220 kDa BRCA1蛋白。它经过验证可用于冷冻和石蜡切片的WB、IF、IP分析。
通过用指定的免疫原免疫小鼠并将脾细胞与NS1小鼠骨髓瘤细胞融合而产生的纯化小鼠单克隆抗体。可识别~220 kDa BRCA1蛋白。
免疫原
人
表位：BRCA1的N末端304个氨基酸内
重组人BRCA1
应用
冰冻切片（见应用参考文献）
免疫印迹（2 µg/ml）
免疫荧光（见应用参考文献）
免疫沉淀（见应用参考文献）
石蜡切片（见应用参考文献）
免疫印迹（2 µg/ml）
免疫荧光（见应用参考文献）
免疫沉淀（见应用参考文献）
石蜡切片（见应用参考文献）
包装
请参考特定浓度批号的标签。
警告
毒性：标准处理（A）
外形
溶于50 mM磷酸钠缓冲液（pH 7.5），含0.2％明胶。
分析说明
阳性对照
MCF7细胞
MCF7细胞
其他说明
Scully, R., et al. 1996.Science272, 123.
Gudas, J.M., et al. 1996.Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996.Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R.1995.Nat. Genet.11, 113.
Merajver, S.D., et al. 1995.Clin. Can.Res.1, 539.
Merajver, S.D., et al. 1995.Nat. Genet.9, 439.
Struewing, J.P., et al. 1995.Nat. Genet.11, 198.
Thompson, M.E., et al. 1995.Nat. Genet.9, 444.
Futreal, P.A., et al. 1994.Science266, 120.
Miki, Y., et al. 1994.Science266, 66.
Wilson, C.A., et al. 1999.Nat. Genet.21, 236.
Gudas, J.M., et al. 1996.Cell Growth Differ.7, 717.
Vaughn, J.P., et al. 1996.Cell Growth Differ.7, 711.
Goldgar, D.E. and Reilly, P.R.1995.Nat. Genet.11, 113.
Merajver, S.D., et al. 1995.Clin. Can.Res.1, 539.
Merajver, S.D., et al. 1995.Nat. Genet.9, 439.
Struewing, J.P., et al. 1995.Nat. Genet.11, 198.
Thompson, M.E., et al. 1995.Nat. Genet.9, 444.
Futreal, P.A., et al. 1994.Science266, 120.
Miki, Y., et al. 1994.Science266, 66.
Wilson, C.A., et al. 1999.Nat. Genet.21, 236.
在单个系统中，应对抗体进行滴定以获得最佳结果。
法律信息
根据美国专利号5,753,441和6,162,897的许可证销售。
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
储存分类代码
10 - Combustible liquids
WGK
nwg
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Pierre Thouvenot et al.
Journal of cell science, 129(23), 4366-4378 (2016-11-02)
Understanding the effect of an ever-growing number of human variants detected by genome sequencing is a medical challenge. The yeast Saccharomyces cerevisiae model has held attention for its capacity to monitor the functional impact of missense mutations found in human
J Xu et al.
International journal of oncology, 34(4), 939-949 (2009-03-17)
BRCA1 dysfunction is associated with hormone-responsive cancers. We have identified a consensus SUMO modification site in the amino-terminal region of BRCA1/1a/1b proteins and the mutation in this potential SUMO acceptor site (K 109 to R) impaired their ability to bind
Geon Kim et al.
Oncology letters, 17(6), 5023-5029 (2019-06-13)
Breast cancer type 1 susceptibility protein (BRCA1) is a tumor suppressor gene that encodes a nuclear phosphoprotein, which is involved in homologous recombination to repair DNA double strand breaks and maintain genome stability. When BRCA1 is mutated or altered, DNA
Nathalie van den Tempel et al.
Cancers, 11(1) (2019-01-18)
The DNA damage response (DDR) is a designation for a number of pathways that protects our DNA from various damaging agents. In normal cells, the DDR is extremely important for maintaining genome integrity, but in cancer cells these mechanisms counteract
Hong Wang et al.
Cancer research, 70(15), 6258-6267 (2010-07-16)
The tumor suppressor BRCA1 is a nuclear shuttling protein. However, the role of BRCA1 localization in the control of its functions remains to be elucidated. Given the central role of BRCA1 in DNA damage repair, we hypothesized that depletion of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门